Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, Solit DB, Shannon K, Chandarlapaty S, Berger MF, Taylor BS.

Cancer Cell. 2018 Nov 12;34(5):852-862.e4. doi: 10.1016/j.ccell.2018.10.003. Epub 2018 Nov 1.

PMID:
30393068
2.

Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.

Yu CC, Qiu W, Juang CS, Mansukhani MM, Halmos B, Su GH.

Cancer Lett. 2017 Jan 1;384:86-93. doi: 10.1016/j.canlet.2016.10.013. Epub 2016 Oct 8. Review.

3.

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.

Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, Varella-Garcia M, Vooder T, Wistuba II, Lam S, Brekken R, Toyooka S, Minna JD, Lam WL, Gazdar AF.

PLoS One. 2009 Oct 14;4(10):e7464. doi: 10.1371/journal.pone.0007464.

4.

Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer.

Gatenby RA, Brown J.

Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):162-166. doi: 10.1016/j.bbcan.2017.03.005. Epub 2017 Mar 21. Review.

5.

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.

Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor BS, Evangelista M, Shannon K.

Cell. 2017 Feb 23;168(5):817-829.e15. doi: 10.1016/j.cell.2017.01.020. Epub 2017 Feb 16.

6.

Irradiation alters selection for oncogenic mutations in hematopoietic progenitors.

Marusyk A, Casás-Selves M, Henry CJ, Zaberezhnyy V, Klawitter J, Christians U, DeGregori J.

Cancer Res. 2009 Sep 15;69(18):7262-9. doi: 10.1158/0008-5472.CAN-09-0604. Epub 2009 Sep 8.

7.

Extracting Fitness Relationships and Oncogenic Patterns among Driver Genes in Cancer.

Zhang X, Gao L, Jia S.

Molecules. 2017 Dec 25;23(1). pii: E39. doi: 10.3390/molecules23010039.

8.

BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors.

Stagni C, Zamuner C, Elefanti L, Zanin T, Bianco PD, Sommariva A, Fabozzi A, Pigozzo J, Mocellin S, Montesco MC, Chiarion-Sileni V, De Nicolo A, Menin C.

Mol Cancer Ther. 2018 Jun;17(6):1332-1340. doi: 10.1158/1535-7163.MCT-17-1124. Epub 2018 Apr 6.

9.

Evolutionary dynamics of chronic myeloid leukemia.

Dingli D, Traulsen A, Lenaerts T, Pacheco JM.

Genes Cancer. 2010 Apr;1(4):309-15. doi: 10.1177/1947601910371122.

10.

The pan-cancer analysis of gain-of-functional mutations to identify the common oncogenic signatures in multiple cancers.

Wee Y, Liu Y, Bhyan SB, Lu J, Zhao M.

Gene. 2019 May 20;697:57-66. doi: 10.1016/j.gene.2019.02.039. Epub 2019 Feb 20.

PMID:
30796966
11.

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.

Kiessling MK, Schuierer S, Stertz S, Beibel M, Bergling S, Knehr J, Carbone W, de Vallière C, Tchinda J, Bouwmeester T, Seuwen K, Rogler G, Roma G.

BMC Genomics. 2016 Sep 9;17(1):723. doi: 10.1186/s12864-016-3042-2.

12.

Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.

Chen X, Makarewicz JM, Knauf JA, Johnson LK, Fagin JA.

Oncogene. 2014 Nov 20;33(47):5442-9. doi: 10.1038/onc.2013.489. Epub 2013 Nov 18.

13.

Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations.

Rozhok AI, DeGregori J.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):8914-21. doi: 10.1073/pnas.1501713112.

14.

Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma.

Zhang JW, Qin T, Hong SD, Zhang J, Fang WF, Zhao YY, Yang YP, Xue C, Huang Y, Zhao HY, Ma YX, Hu ZH, Huang PY, Zhang L.

Chin J Cancer. 2015 Apr 8;34(4):177-83. doi: 10.1186/s40880-015-0011-0.

15.

Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.

Koo T, Yoon AR, Cho HY, Bae S, Yun CO, Kim JS.

Nucleic Acids Res. 2017 Jul 27;45(13):7897-7908. doi: 10.1093/nar/gkx490.

16.

Negative clonal selection in tumor evolution.

Beckman RA, Loeb LA.

Genetics. 2005 Dec;171(4):2123-31. Epub 2005 Sep 2.

17.

Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers.

Staff S, Nupponen NN, Borg A, Isola JJ, Tanner MM.

Genes Chromosomes Cancer. 2000 Aug;28(4):432-42.

PMID:
10862052
18.

Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.

Haley L, Tseng LH, Zheng G, Dudley J, Anderson DA, Azad NS, Gocke CD, Eshleman JR, Lin MT.

Mod Pathol. 2015 Oct;28(10):1390-9. doi: 10.1038/modpathol.2015.86. Epub 2015 Jul 31.

19.

Successes and limitations of targeted cancer therapy in lung cancer.

Suda K, Mitsudomi T.

Prog Tumor Res. 2014;41:62-77. doi: 10.1159/000355902. Epub 2014 Feb 17. Review.

PMID:
24727987
20.

Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis.

Henry CJ, Marusyk A, Zaberezhnyy V, Adane B, DeGregori J.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21713-8. doi: 10.1073/pnas.1005486107. Epub 2010 Nov 22.

Supplemental Content

Support Center